ABSTRACT
AIMS: Appendiceal mucinous neoplasms feature neoplastic mucinous epithelium with pushing borders and densely fibrotic walls. We have identified five examples of analogous colorectal tumours. METHODS AND RESULTS: Slides, pathology reports, and clinical data were reviewed. Whole genome sequencing was performed in two cases. Three were women and the mean age was 70. Associated GI conditions included Crohn's disease [1], diverticulosis [2], and sarcoma of the terminal ileum [1]. Signs/symptoms included obstruction [2], nausea, vomiting, abdominal pain [1], and positive faecal immunohistochemical test [1]. Colonoscopic findings included narrowing [1], "fullness" [1], and caecal lesion concerning for GIST [1]. Tumours involved the rectosigmoid [2], sigmoid [1], transverse colon [1], and cecum [1] and ranged from 1.5 cm to 8.5 cm. All but one tumour arose in the setting of faecal stream abnormalities related to obstruction, diverticulosis, or bowel diversion. All cases showed columnar, variably mucinous epithelium associated with little-to-no lamina propria. All but one case showed fibrosis of the submucosa. Three cases had high-grade areas. Neoplastic glands and/or mucin dissected through the muscularis propria or subserosa in 3 examples. No extracolonic neoplastic cells/mucin, infiltrative invasion, or desmoplastic response were identified. Three patients with available follow-up [5.5-28 months] are alive. Whole genome sequencing identified pathogenic TP53 and ERBB2 variants, as well as ERBB2 copy number amplification in one high-grade example. CONCLUSIONS: Though these tumours share clinicopathologic characteristics with their appendiceal counterparts, our cohort is too small to draw solid conclusions. We propose the term "extra-appendiceal mucinous neoplasm [EAMN]" for these rare lesions.
Subject(s)
Adenocarcinoma, Mucinous , Appendiceal Neoplasms , Humans , Female , Male , Aged , Middle Aged , Adenocarcinoma, Mucinous/pathology , Adenocarcinoma, Mucinous/genetics , Appendiceal Neoplasms/pathology , Appendiceal Neoplasms/genetics , Appendiceal Neoplasms/chemistry , Biomarkers, Tumor/genetics , Biomarkers, Tumor/analysis , Aged, 80 and over , Neoplasm Grading , Whole Genome Sequencing , MutationABSTRACT
Appendiceal mucinous neoplasms show a range of morphologic features and biological risk. At one end of the spectrum, high-grade adenocarcinomas are cytologically malignant with infiltrative invasion, lymph node metastases, and behavior similar to that of extra-appendiceal mucinous adenocarcinomas. At the other end, mucinous neoplasms confined to the mucosa are uniformly benign. Some cases lying between these extremes have potential risk to metastasize within the abdomen despite a lack of malignant histologic features. They show "diverticulum-like," pushing invasion of mostly low-grade epithelium through the appendix with, or without, concomitant organizing intra-abdominal mucin. The latter condition, widely termed "pseudomyxoma peritonei," tends to pursue a relentless course punctuated by multiple recurrences despite cytoreductive therapy, culminating in death for many patients. The combination of bland histologic features and protracted behavior of peritoneal disease has led some authors to question whether these metastatic tumors even represent malignancies. The World Health Organization and its cadre of experts widely promote usage of "low-grade appendiceal mucinous neoplasm" as an umbrella term to encompass benign and malignant conditions, as well as those that have uncertain biological potential. Although this practice greatly simplifies tumor classification, it causes confusion and consternation among pathologists, clinical colleagues, and patients. It also increases the likelihood that at least some patients will undergo unnecessary surveillance for, and treatment of, benign neoplasms and non-neoplastic conditions. The purpose of this review is to critically evaluate the relevant literature and discuss a practical approach to classifying appendiceal mucinous neoplasms that more closely approximates their biological risk.
Subject(s)
Appendiceal Neoplasms/pathology , Appendix/pathology , Neoplasms, Cystic, Mucinous, and Serous/pathology , Pseudomyxoma Peritonei/pathology , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/therapy , Appendix/chemistry , Biomarkers, Tumor/analysis , Biopsy , Clinical Decision-Making , Humans , Neoplasm Grading , Neoplasms, Cystic, Mucinous, and Serous/chemistry , Neoplasms, Cystic, Mucinous, and Serous/therapy , Predictive Value of Tests , Pseudomyxoma Peritonei/chemistry , Pseudomyxoma Peritonei/therapy , Risk Assessment , Risk FactorsABSTRACT
Low-grade appendiceal mucinous neoplasms (LAMN) can disseminate to become low-grade mucinous carcinoma peritonei (LGMCP), which is optimally treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). Approximately half of the patients with LGMCP recur despite complete cytoreduction, and risk factors for recurrence are poorly understood. We sought to evaluate if Ki67 predicts progression of LGMCP after CRS/HIPEC. A retrospective review of a prospectively maintained database was performed to identify patients treated with complete CRS/HIPEC for LGMCP from 2008 to 2019 with Ki67 assessed. Patient characteristics, histologic data, average and focally high "hotspot") Ki67 index, progression-free survival (PFS), and overall survival (OS) were analyzed. Ki-67 immunostain was performed on the histologic section with the highest cellularity and architectural complexity. Forty-four patients with LGMCP (55% male, median age 61) were identified. The median Ki67 score and hotspot Ki67 score was 15% (1-70) and 50% (1-90), respectively. On univariate analysis, average Ki67 and hotspot Ki67 were not predictive of PFS when analyzed as continuous normalized values (HR 1.0, p = 0.79 and HR 1.1, p = 0.38, respectively) or as categorical values when stratified by the median (HR 0.9, p = 0.67 and HR 1.0, p = 0.93). This remained true on multivariate analysis when stratified for peritoneal cancer index, CEA, and completeness of cytoreduction score for both normalized Ki67 and hotspot Ki67 (HR 0.9 [95% CI 0.8-1.3], p = 0.94 and HR 1.04 [95% CI 0.8-1.3], p = 0.73, respectively). Ki67 failed to predict disease recurrence for patients with LGMCP in this cohort.
Subject(s)
Adenocarcinoma, Mucinous/therapy , Appendiceal Neoplasms/therapy , Cytoreduction Surgical Procedures , Hyperthermic Intraperitoneal Chemotherapy , Ki-67 Antigen/analysis , Neoplasm Recurrence, Local , Peritoneal Neoplasms/therapy , Adenocarcinoma, Mucinous/chemistry , Adenocarcinoma, Mucinous/mortality , Adenocarcinoma, Mucinous/secondary , Adult , Aged , Aged, 80 and over , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/mortality , Appendiceal Neoplasms/pathology , Chemotherapy, Adjuvant , Cytoreduction Surgical Procedures/adverse effects , Cytoreduction Surgical Procedures/mortality , Databases, Factual , Female , Humans , Hyperthermic Intraperitoneal Chemotherapy/adverse effects , Hyperthermic Intraperitoneal Chemotherapy/mortality , Male , Middle Aged , Neoplasm Grading , Peritoneal Neoplasms/chemistry , Peritoneal Neoplasms/mortality , Peritoneal Neoplasms/secondary , Progression-Free Survival , Retrospective Studies , Risk Assessment , Risk Factors , Time FactorsABSTRACT
Appendiceal mucinous tumors (AMTs) include low-grade mucinous appendiceal neoplasms (LAMNs), high-grade mucinous appendiceal neoplasms (HAMNs), and mucinous adenocarcinomas (MACs). We collected 51 AMT samples (LAMN: 34, HAMN: 8, MAC: 9). Three of the eight HAMN cases contained LAMN components, and four out of nine MAC cases contained LAMN and/or HAMN components within the tumor. A next-generation sequencing (NGS) cancer hotspot panel was used to analyze 11 pure LAMN, 4 HAMN, and 3 MAC cases. The results revealed KRAS and GNAS as the most frequently mutated genes. Sanger sequencing was then performed to detect KRAS, GNAS, and TP53 mutations in the remaining 31 cases and RNF43 mutations in all cases. KRAS/GNAS and TP53 mutations occurred exclusively in pure LAMNs; however, five LAMN cases had mutations in both KRAS and GNAS. RNF43 mutations almost exclusively occurred with KRAS/GNAS mutations in pure LAMNs. In MAC and HAMN, KRAS/GNAS mutation status was nearly preserved between lower-grade areas. Most of the detected RNF43 mutations was missense type. RNF43 mutations were detected in both components of MAC with lower-grade area; however, RNF43 mutations detected in these two lesions were entirely different. RNF43 mutations were detected in only one of the eight HAMN patients, which was the sole case without pseudomyxoma peritonei (PMP). None of the four MAC patients with RNF43 mutation showed PMP. These findings suggest that RNF43 mutations occur at a later stage of MAC development and do not associate with PMP. Furthermore, a gradual transition from LAMN to MAC via HAMN could be considered.
Subject(s)
Adenocarcinoma, Mucinous/genetics , Appendiceal Neoplasms/genetics , Biomarkers, Tumor/genetics , Mutation , Adenocarcinoma, Mucinous/chemistry , Adenocarcinoma, Mucinous/pathology , Adenocarcinoma, Mucinous/surgery , Adult , Aged , Aged, 80 and over , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/pathology , Appendiceal Neoplasms/surgery , Biomarkers, Tumor/analysis , Chromogranins/genetics , DNA Mutational Analysis , Female , GTP-Binding Protein alpha Subunits, Gs/genetics , High-Throughput Nucleotide Sequencing , Humans , Immunohistochemistry , Loss of Heterozygosity , Male , Middle Aged , Neoplasm Grading , Neoplasm Staging , Proto-Oncogene Proteins p21(ras)/genetics , Tokyo , Tumor Suppressor Protein p53/genetics , Ubiquitin-Protein Ligases/genetics , Young AdultABSTRACT
INTRODUCTION: Goblet cell carcinoma (GCC) is an appendicular neoplasia representing less than 5% of all appendicular tumors, found in 0.3-0.9% of the appendectomies, 35-58% of all appendicular neoplasms, and less than 14% of malign appendix tumors. The most frequent clinical presentation is abdominal pain associated with a picture of acute appendicitis. MATERIALS AND METHODS: We present 3 clinical cases of appendix GCC, 2 subjected to cytoreductory surgery plus intraperitoneal hyperthermic chemotherapy and a third, who is currently receiving neoadjuvant treatment with a good response to chemotherapy and who will be offered the same treatment as the first two patients. Given the unpredictable behavior of these tumors, the use of molecular markers could help us to predict their behavior and prognosis. In this context, the TP73 gene would make an interesting putative marker. ∆Np73 has been described as overexpressed in a great variety of tumor types including colon cancer and this up-regulation is associated with a poor prognosis. To evidence its role in this malignancy, we evaluate here the status of ∆Np73 in the primary tumor and normal counterpart tissues, in the metastatic implants and in healthy areas of the peritoneum from the appendicular GCC patients. In addition, we checked the expression levels of this p73 variant in the tumor and normal tissue of 26 patients with colon cancer. RESULTS: Remarkably, 2 patients showed significant ∆Np73 down-regulation in both the primary tumor and the implants. Case 1 presented a fourfold decrease of levels in the primary tumor and 20-fold decrease in the implants. Case 2 showed a seven- and fourfold down-regulation in the primary tumor and implants, respectively. However, Case 3 showed an up-regulation of 53- and threefold in the primary tumor and implants, respectively. CONCLUSION: Goblet cell carcinoma of the appendix is very rate. It tends to seed throughout the peritoneum, making aggressive surgical cytoreduction and chemotherapy viable treatment options. Investigation into the molecular basis of these tumors may improve the diagnosis, prognosis and therapeutic decisions regarding these patients. ∆Np73 seems a good candidate for further analysis in longer series.
Subject(s)
Adenocarcinoma/chemistry , Appendiceal Neoplasms/chemistry , Biomarkers, Tumor/analysis , Goblet Cells/chemistry , Ovarian Neoplasms/chemistry , Peritoneal Neoplasms/chemistry , Tumor Protein p73/analysis , Adenocarcinoma/secondary , Adenocarcinoma/therapy , Appendiceal Neoplasms/pathology , Appendiceal Neoplasms/therapy , Colon/chemistry , Colonic Neoplasms/chemistry , Cytoreduction Surgical Procedures , Down-Regulation , Female , Humans , Hyperthermia, Induced , Male , Middle Aged , Ovarian Neoplasms/secondary , Peritoneal Neoplasms/secondary , Peritoneum/chemistryABSTRACT
Goblet cell carcinoid (GCC) or goblet cell carcinoma is a unique mixed endocrine-exocrine neoplasm that is almost exclusively seen in the appendix. The hallmark of GCC is the concentric infiltration of the appendiceal wall by small tight clusters, nests or cords of tumor cells that exhibit a goblet cell morphology with a small compressed nucleus and conspicuous intracytoplasmic mucin. The coexistence of high-grade adenocarcinoma with GCC has been increasingly recognized as a common finding, which has been called adenocarcinoma ex GCC or mixed GCC-adenocarcinoma. A number of studies have shown that it is the high-grade adenocarcinomatous component that dictates the prognosis. Several histologic classification/grading systems have been proposed, which correlate with overall patient survival. Treatment options are primarily based on tumor stage and the presence or absence of a high-grade adenocarcinomatous component.
Subject(s)
Adenocarcinoma/pathology , Appendiceal Neoplasms/pathology , Carcinoid Tumor/pathology , Goblet Cells/pathology , Neoplasms, Complex and Mixed/pathology , Adenocarcinoma/chemistry , Adenocarcinoma/mortality , Adenocarcinoma/therapy , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/mortality , Appendiceal Neoplasms/therapy , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , Biopsy , Carcinoid Tumor/chemistry , Carcinoid Tumor/mortality , Carcinoid Tumor/therapy , Goblet Cells/chemistry , Humans , Immunohistochemistry , Molecular Diagnostic Techniques , Neoplasm Grading , Neoplasm Staging , Neoplasms, Complex and Mixed/chemistry , Neoplasms, Complex and Mixed/mortality , Neoplasms, Complex and Mixed/therapy , Treatment OutcomeABSTRACT
A major problem in neuroendocrine pathology is the identification and separation of aggressive low-grade neuroendocrine tumors (LGNETs) from those with a benign or more indolent behavior. Presently there are no known morphologic or molecular parameters which can predict how localized LGNETs will behave. The phosphatase and tensin homolog (PTEN) gene negatively regulates the PI3K-AKT-mTOR pathway and inhibits neoplastic cell survival and proliferation and has recently been identified as a neuroendocrine tumor differentiation marker. We hypothesized loss of PTEN may also identify LGNETs that demonstrate aggressive behavior. We studied PTEN and pAKT expression in 18 LGNETs using specific monoclonal antibodies. Follow up was obtained for a minimum of five years on all patients. 8/18 cases had strong PTEN expression and showed no evidence of disease on >5 years follow-up. 10 cases demonstrated loss of PTEN expression; 9/10 had positive pAKT expression, and 7/9 had recurrence and/or metastases. Lung and appendiceal LGNETs uniformly had high PTEN expression and a markedly better prognosis than their gastroenteropancreatic (GEP) counterparts. Loss of PTEN correlated significantly with the positive expression of pAKT (P=0.0027) and aggressive behavior of LGNETs (p=0.0002). Loss of PTEN and increased pAKT correlated with the metastatic potential of LGNETs (p=0.0011 and 0.0248 respectively). Loss of PTEN and increased pAKT expression distinguishes aggressive LGNETs from those with more indolent behavior.
Subject(s)
Neuroendocrine Tumors/pathology , PTEN Phosphohydrolase/analysis , Proto-Oncogene Proteins c-akt/metabolism , Adult , Aged , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/pathology , Female , Humans , Intestinal Neoplasms/chemistry , Intestinal Neoplasms/pathology , Lung Neoplasms/chemistry , Lung Neoplasms/pathology , Male , Middle Aged , Neuroendocrine Tumors/chemistry , Pancreatic Neoplasms/chemistry , Pancreatic Neoplasms/pathology , Phosphorylation , Stomach Neoplasms/chemistry , Stomach Neoplasms/pathology , TOR Serine-Threonine Kinases/physiologyABSTRACT
Goblet cell carcinoid (GCC) is staged and treated as adenocarcinoma (AC) and not as neuroendocrine tumor (NET) or neuroendocrine carcinoma. The term carcinoid may lead to incorrect interpretation as NET. The aim of the study was to explore pitfalls in staging and clinical interpretation of GCC and mixed GCC-AC, and propose strategies to avoid common errors. Diagnostic terminology, staging, and clinical interpretation were evaluated in 58 cases (27 GCCs, 31 mixed GCC-ACs). Opinions were collected from 23 pathologists using a survey. Clinical notes were reviewed to assess the interpretation of pathology diagnoses by oncologists. NET staging was incorrectly used for 25% of GCCs and 5% of mixed GCC-ACs. In the survey, 43% of pathologists incorrectly indicated that NET staging is applicable to GCCs, and 43% incorrectly responded that Ki-67 proliferation index is necessary for GCC grading. Two cases each of GCC and mixed GCC-AC were incorrectly interpreted as neuroendocrine neoplasms by oncologists, and platinum-based therapy was considered for 2 GCC-AC cases because of the mistaken impression of neuroendocrine carcinoma created by use of the World Health Organization 2010 term mixed adenoneuroendocrine carcinoma. The term carcinoid in GCC and use of mixed adenoneuroendocrine carcinoma for mixed GCC-AC lead to errors in staging and treatment. We propose that goblet cell carcinoid should be changed to goblet cell carcinoma, whereas GCC with AC should be referred to as mixed GCC-AC with a comment about the proportion of each component and the histologic subtype of AC. This terminology will facilitate appropriate staging and clinical management, and avoid errors in interpretation.
Subject(s)
Adenocarcinoma/pathology , Appendiceal Neoplasms/pathology , Carcinoid Tumor/pathology , Carcinoma, Neuroendocrine/pathology , Neoplasms, Complex and Mixed/pathology , Terminology as Topic , Adenocarcinoma/chemistry , Adenocarcinoma/classification , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/classification , Carcinoid Tumor/chemistry , Carcinoid Tumor/classification , Carcinoma, Neuroendocrine/chemistry , Carcinoma, Neuroendocrine/classification , Consensus , Databases, Factual , Diagnosis, Differential , Diagnostic Errors , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Neoplasm Staging , Neoplasms, Complex and Mixed/chemistry , Neoplasms, Complex and Mixed/classification , Predictive Value of Tests , Retrospective Studies , Surveys and QuestionnairesABSTRACT
The primary origin of some ovarian mucinous tumors may be challenging to determine, because some metastases of extraovarian origin may exhibit gross, microscopic, and immunohistochemical features that are shared by some primary ovarian mucinous tumors. Metastases of primary colorectal, appendiceal, gastric, pancreatic, and endocervical adenocarcinomas may simulate primary ovarian mucinous cystadenoma, mucinous borderline tumor, or mucinous adenocarcinoma. Recently, immunohistochemical expression of SATB2, a transcriptional regulator involved in osteoblastic and neuronal differentiation, has been shown to be a highly sensitive marker of normal colorectal epithelium and of colorectal adenocarcinoma. SATB2 expression has not been reported in normal epithelium of the female reproductive tract. Therefore, we hypothesized that SATB2 may be of value in distinguishing ovarian metastases of colorectal adenocarcinoma from primary ovarian mucinous tumors and from primary ovarian endometrioid tumors. Among primary ovarian tumors, SATB2 staining was observed in 0/22 mucinous cystadenomas that lacked a component of mature teratoma, 4/12 mucinous cystadenomas with mature teratoma, 1/60 mucinous borderline tumors, 0/17 mucinous adenocarcinomas, 0/3 endometrioid borderline tumors, and 0/72 endometrioid adenocarcinomas. Among ovarian metastases, SATB2 staining was observed in 24/32 (75%) colorectal adenocarcinomas; 8/10 (80%) low-grade appendiceal mucinous neoplasms; and 4/4 (100%) high-grade appendiceal adenocarcinomas. No SATB2 staining was observed in any ovarian metastasis of pancreatic, gastric, gallbladder, or endocervical origin. Evaluation of primary extraovarian tumors showed the highest incidences of SATB2 staining among primary colorectal adenocarcinomas (71%), primary appendiceal low-grade mucinous neoplasms (100%), and primary appendiceal high-grade adenocarcinomas (100%). Similar to their metastatic counterparts, none of the primary pancreatic or gastric adenocarcinomas showed any SATB2 staining. In a subset of tumors for which CK7, CK20, and CDX2 were available, SATB2 was never positive in any tumor of any origin that was CK7+CK20-CDX2-. Among tumors that coexpressed all 3 markers (CK7+CK20+CDX2+), 6/7 SATB2 tumors were of colorectal or appendiceal origin, and 1/7 was a primary ovarian borderline tumor. We conclude that ovarian tumors with mucinous or endometrioid features that express SATB2 are unlikely to be of primary ovarian origin unless there is a component of mature teratoma in the ovary; instead, attention should be directed to a colorectal or appendiceal origin. SATB2 may be of particular value in ovarian mucinous tumors that are positive for all 3 markers (CK7+CK20+CDX2+), as SATB2 staining strongly implicates a colorectal or appendiceal origin.
Subject(s)
Adenocarcinoma/chemistry , Appendiceal Neoplasms/chemistry , Biomarkers, Tumor/analysis , Carcinoma, Endometrioid/chemistry , Colorectal Neoplasms/chemistry , Matrix Attachment Region Binding Proteins/analysis , Neoplasms, Cystic, Mucinous, and Serous/chemistry , Ovarian Neoplasms/chemistry , Transcription Factors/analysis , Adenocarcinoma/secondary , Appendiceal Neoplasms/pathology , Biopsy , Carcinoma, Endometrioid/pathology , Colorectal Neoplasms/pathology , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Neoplasm Grading , Neoplasms, Cystic, Mucinous, and Serous/pathology , Ovarian Neoplasms/pathology , Ovarian Neoplasms/secondary , Predictive Value of TestsABSTRACT
Pseudomyxoma peritonei (PMP) is a complex disease with unique biological behavior that usually arises from appendiceal mucinous neoplasia. The classification of PMP and its primary appendiceal neoplasia is contentious, and an international modified Delphi consensus process was instigated to address terminology and definitions. A classification of mucinous appendiceal neoplasia was developed, and it was agreed that "mucinous adenocarcinoma" should be reserved for lesions with infiltrative invasion. The term "low-grade appendiceal mucinous neoplasm" was supported and it was agreed that "cystadenoma" should no longer be recommended. A new term of "high-grade appendiceal mucinous neoplasm" was proposed for lesions without infiltrative invasion but with high-grade cytologic atypia. Serrated polyp with or without dysplasia was preferred for tumors with serrated features confined to the mucosa with an intact muscularis mucosae. Consensus was achieved on the pathologic classification of PMP, defined as the intraperitoneal accumulation of mucus due to mucinous neoplasia characterized by the redistribution phenomenon. Three categories of PMP were agreed-low grade, high grade, and high grade with signet ring cells. Acellular mucin should be classified separately. It was agreed that low-grade and high-grade mucinous carcinoma peritonei should be considered synonymous with disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis, respectively. A checklist for the pathologic reporting of PMP and appendiceal mucinous neoplasms was also developed. By adopting the classifications and definitions that were agreed, different centers will be able to use uniform terminology that will allow meaningful comparison of their results.
Subject(s)
Appendiceal Neoplasms/pathology , Delphi Technique , Neoplasms, Cystic, Mucinous, and Serous/pathology , Peritoneal Neoplasms/pathology , Pseudomyxoma Peritonei/pathology , Terminology as Topic , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/classification , Biomarkers, Tumor/analysis , Biopsy , Checklist , Consensus , Humans , Lymphatic Metastasis , Mucins/analysis , Mucus/metabolism , Neoplasm Grading , Neoplasm Invasiveness , Neoplasms, Cystic, Mucinous, and Serous/chemistry , Neoplasms, Cystic, Mucinous, and Serous/classification , Peritoneal Neoplasms/chemistry , Peritoneal Neoplasms/classification , Predictive Value of Tests , Pseudomyxoma Peritonei/classification , Pseudomyxoma Peritonei/metabolismABSTRACT
We report a case of a 30-year-old woman who had complained of lower abdominal distension. She was noted to have a history of primary mucinous tumor of the left ovary (13.2 × 9.9 × 10.4 cm) that was removed surgically. Two years later she developed the same tumor on her left ovary (8.7 × 6.0 × 6.9 cm) and also had appendiceal mucinous tumor accompanied with acellular PMP. Final pathology revealed two truly independent primary mucinous tumors involving the appendix and ovary accompanied with acellular PMP. We recommend a minimum follow-up of 5 years for the patient to detect any development of mucinous tumors and the acellular pseudomyxoma peritonei.
Subject(s)
Appendiceal Neoplasms/pathology , Neoplasms, Cystic, Mucinous, and Serous/pathology , Neoplasms, Multiple Primary/pathology , Ovarian Neoplasms/pathology , Peritoneal Neoplasms/pathology , Pseudomyxoma Peritonei/pathology , Adult , Appendectomy , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/surgery , Biomarkers, Tumor/analysis , Biopsy , Female , Humans , Immunohistochemistry , Neoplasms, Cystic, Mucinous, and Serous/chemistry , Neoplasms, Cystic, Mucinous, and Serous/surgery , Neoplasms, Multiple Primary/chemistry , Neoplasms, Multiple Primary/surgery , Ovarian Neoplasms/chemistry , Ovarian Neoplasms/surgery , Ovariectomy , Peritoneal Neoplasms/chemistry , Peritoneal Neoplasms/surgery , Pseudomyxoma Peritonei/metabolism , Pseudomyxoma Peritonei/surgery , Time Factors , Tumor BurdenABSTRACT
Appendiceal mucinous tumors (AMTs) are classified as low-grade appendiceal mucinous neoplasms (LAMNs) or mucinous adenocarcinomas (MACs), although their carcinogenesis is not well understood. As somatic activating mutations of GNAS are considered to be characteristic of LAMNs while TP53 mutations have been shown to be specific to MACs, MACs are unlikely to result from transformation of LAMNs. However, emerging evidence also shows the presence of GNAS mutations in MACs. We examined 16 AMTs (11 LAMNs and 5 MACs) for genetic alterations of GNAS, KRAS, BRAF, TP53, CTNNB1, and TERT promoter in order to elucidate the possibility of a shared genetic background in the two tumor types. Extensive histological examination revealed the presence of a low-grade component in all cases of MAC. GNAS mutations were detected in two LAMNs and in one MAC, although the GNAS mutation in this MAC was a nonsense mutation (Q227X) expected not to be activating mutation. TP53 mutations were detected in three LAMNs; they were frequently detected in MACs. KRAS mutations were detected in three LAMNs and three MACs, and CTNNB1 mutations were detected in two LAMNs. KRAS mutation and activating mutation of GNAS occurred exclusively in AMTs. BRAF and TERT mutations were not detected. Overexpression of p53 was observed in only two MACs, and p53 immunostaining clearly discriminated the high-grade lesion from a low-grade component in one. These findings suggest that p53 overexpression plays an important role in the carcinogenesis of AMTs and that, in addition to mutations of GNAS, KRAS and TP53 alterations might be shared by AMTs, thus providing evidence for the possible progression of LAMNs to MAC.
Subject(s)
Adenocarcinoma, Mucinous/genetics , Appendiceal Neoplasms/genetics , Biomarkers, Tumor/genetics , GTP-Binding Protein alpha Subunits, Gs/genetics , Mutation , Proto-Oncogene Proteins p21(ras)/genetics , Tumor Suppressor Protein p53/genetics , Adenocarcinoma, Mucinous/chemistry , Adenocarcinoma, Mucinous/pathology , Adenocarcinoma, Mucinous/therapy , Adult , Aged , Aged, 80 and over , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/pathology , Appendiceal Neoplasms/therapy , Biomarkers, Tumor/analysis , Chromogranins , DNA Mutational Analysis , Female , Genetic Predisposition to Disease , Humans , Immunohistochemistry , Male , Middle Aged , Neoplasm Grading , Phenotype , Predictive Value of Tests , Promoter Regions, Genetic , Telomerase/genetics , Tumor Suppressor Protein p53/analysis , beta Catenin/geneticsABSTRACT
BACKGROUND: Gastroenteropancreatic neuroendocrine tumors (GNs) are slow growing and although their incidence has increased in recent years, they are relatively rarely seen. Somatostatin analogues are used in the treatment of GNs that express somatostatin receptor (SR). We aimed to investigate the expression of SR2 and SR5 in GNs. MATERIALS AND METHODS: In this study the expression of SR2 and SR5 was investigated immunohistochemically in 49 cases (26 males, 23 females) diagnosed and graded with GN according to the World Health Organization classification 2010. RESULTS: The percentage of SR2 staining was 91.0% in grade 1, 82.8% in grade 2 and 100% in grade 3. On the other hand, the percentage of SR5 staining was 81.8% % in grade 1, 60.0% in grade 2 and 0% in grade 3. According to the tumor localization, the percentages of SR2 expression were as follows: pancreas 85.7%, stomach 100%, small bowel 70%, appendix 85.7% and rectum 100%. The percentages of SR5 expression were: pancreas 61,9%, stomach 37.5%, small bowel 70%, appendix 71.5% and rectum 66.6%. There was a significant negative correlation between ki67 percentage and SR5 expression (r=-0.341, p=0.016). CONCLUSIONS: In this study, GNs were found to highly express SR2 and SR5. Although the expression of SR2 and SR5 changed according to tumor localization, the expression of SR2 was higher than the expression of SR5 in GN. There was a significant negative correlation between ki67 and SR5. Accordingly, SR5 may be a prognostic indicator of GN.
Subject(s)
Gastrointestinal Neoplasms/chemistry , Neuroendocrine Tumors/chemistry , Pancreatic Neoplasms/chemistry , Receptors, Somatostatin/analysis , Adult , Aged , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/pathology , Female , Gastrointestinal Neoplasms/pathology , Humans , Ki-67 Antigen/analysis , Male , Middle Aged , Neoplasm Grading , Neuroendocrine Tumors/pathology , Pancreatic Neoplasms/pathology , Rectal Neoplasms/chemistry , Rectal Neoplasms/pathology , Stomach Neoplasms/chemistry , Stomach Neoplasms/pathology , TurkeyABSTRACT
VIRTUAL SLIDES: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1006600359152743.
Subject(s)
Appendiceal Neoplasms/pathology , Lymph Nodes/pathology , Neuroendocrine Tumors/secondary , Appendectomy/methods , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/surgery , Biomarkers, Tumor/analysis , Biopsy , Child , Colectomy , Female , Humans , Immunohistochemistry , Laparoscopy , Lymph Node Excision , Lymph Nodes/chemistry , Lymph Nodes/surgery , Lymphatic Metastasis , Neuroendocrine Tumors/chemistry , Neuroendocrine Tumors/surgery , Tomography, X-Ray Computed , Treatment OutcomeABSTRACT
Goblet cell carcinoid of the appendix is a rare neuoroendocrine tumor that possesses histological features of both adenocarcinoma and neuoroendocrine tumor. Goblet cell carcinoid of the appendix is more aggressive than conventional neuroendocrine tumors. Here we report a case of a 54-year-old woman with goblet cell carcinoid tumor in the appendix.
Subject(s)
Appendiceal Neoplasms/pathology , Carcinoid Tumor/pathology , Appendiceal Neoplasms/chemistry , Biomarkers, Tumor/analysis , Biopsy , Carcinoid Tumor/chemistry , Female , Humans , Immunohistochemistry , Middle AgedABSTRACT
The gastrointestinal tract is the most common site for extranodal involvement by non-Hodgkin's lymphoma. However, primary appendiceal lymphomas presenting as perforated acute appendicitis are very rare: they occur in only 0.015% of all gastrointestinal lymphoma cases. The management of this condition is still controversial, and a multimodality approach (e.g., surgery, radiation therapy, and chemotherapy) is the optimal treatment. In these cases, appendiceal non-Hodgkin's lymphomas typically manifest with acute symptoms in patients with no prior lymphoma history. Additionally, we treated our patient with a right hemicolectomy and postoperative multiagent chemotherapy.
Subject(s)
Appendiceal Neoplasms/diagnosis , Appendicitis/diagnosis , Lymphoma, Large B-Cell, Diffuse/diagnosis , Tomography, X-Ray Computed , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Appendectomy , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/diagnostic imaging , Appendiceal Neoplasms/pathology , Appendiceal Neoplasms/surgery , Biomarkers, Tumor/analysis , Biopsy , Chemotherapy, Adjuvant , Colectomy , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Lymph Node Excision , Lymphoma, Large B-Cell, Diffuse/chemistry , Lymphoma, Large B-Cell, Diffuse/diagnostic imaging , Lymphoma, Large B-Cell, Diffuse/pathology , Lymphoma, Large B-Cell, Diffuse/surgery , Neoplasm Invasiveness , Predictive Value of Tests , Reoperation , Treatment Outcome , UltrasonographyABSTRACT
Microcystic/reticular schwannoma is a recently described variant of schwannoma with a predilection for the gastrointestinal tract. Due to overlapping features with other tumors, unawareness of this tumor type may lead to diagnostic and therapeutic pitfalls. We here report a case of microcystic/reticular schwannoma arising in the meso-appendix of a 43-year-old woman. The tumor was incidentally discovered by computed tomography scan for unrelated reasons. A laparoscopic operation was performed shortly after admission. Histological examination revealed a circumscribed tumor with a striking microcystic and cribriform architecture. Immunohistochemically, the tumor cells were diffusely positive for S100 protein, glial fibrillary acid protein and protein gene product 9.5, which were consistent with a peripheral nerve sheath tumor. The patient remains well with no signs of recurrence at a 10-mo follow-up. To our knowledge, this is the first case of microcystic/reticular schwannoma arising in the meso-appendix. Albeit very rare, microcystic/reticular schwannoma should be included in the differential diagnosis of appendiceal tumors.
Subject(s)
Appendiceal Neoplasms , Neurilemmoma , Adult , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/diagnostic imaging , Appendiceal Neoplasms/pathology , Appendiceal Neoplasms/surgery , Biomarkers, Tumor/analysis , Biopsy , Female , Humans , Immunohistochemistry , Incidental Findings , Laparoscopy , Neurilemmoma/chemistry , Neurilemmoma/diagnostic imaging , Neurilemmoma/pathology , Neurilemmoma/surgery , Tomography, X-Ray ComputedABSTRACT
BACKGROUND: The debate remains whether appendiceal goblet cell cancers behave as classical carcinoid or adenocarcinoma. Treatment options are unclear and reports of outcomes are scarce. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS+HIPEC) is considered optimal treatment for peritoneal involvement of other epithelial appendiceal tumors. METHODS: Prospective cohorts of patients treated for advanced appendiceal tumors from three peritoneal malignancy centres were collected (1994-2011). All patients underwent complete CRS+HIPEC, when possible, or tumor debulking. Demographic and outcome data for patients with goblet cell cancers were compared to patients with low- or high-grade epithelial appendiceal tumors treated during the same time period. RESULTS: Details on 45 goblet cell cancer patients were compared to 708 patients with epithelial appendix lesions. In the goblet cell group, 57.8 % were female, median age was 53 years, median peritoneal cancer index (PCI) was 24, and CRS+HIPEC was achieved in 71.1 %. These details were similar in patients with low- or high-grade epithelial tumors. Lymph nodes were involved in 52 % of goblet cell patients, similar to rates in high-grade cancers, but significantly higher than in low-grade lesions (6.4 %; p < 0.001). At 3 years, overall survival (OS) was 63.4 % for goblet cell patients, intermediate between that for high-grade (40.4-52.2 %) and low-grade (80.6 %) tumors. On multivariate analysis, tumor histology, PCI, and achievement of CRS+HIPEC were independently associated with OS. CONCLUSIONS: This data supports the concept that appendiceal goblet cell cancers behave more as high-grade adenocarcinomas than as low-grade lesions. These patients have reasonable long-term survival when treated using CRS+HIPEC, and this strategy should be considered.
Subject(s)
Adenocarcinoma/therapy , Appendiceal Neoplasms/pathology , Appendiceal Neoplasms/therapy , Carcinoid Tumor/pathology , Carcinoid Tumor/therapy , Cytoreduction Surgical Procedures , Hyperthermia, Induced , Adenocarcinoma/chemistry , Adenocarcinoma/pathology , Antibiotics, Antineoplastic/administration & dosage , Appendiceal Neoplasms/chemistry , Carcinoembryonic Antigen/analysis , Carcinoid Tumor/chemistry , Disease-Free Survival , Female , Humans , Keratin-20/analysis , Keratin-7/analysis , Male , Middle Aged , Mitomycin/administration & dosage , Neoplasm Grading , Retrospective Studies , Survival RateABSTRACT
Mucinous lesions of the appendix and ovary are commonly encountered in routine practice. There are several published classification schemes for appendiceal mucinous neoplasms with resultant inconsistent use of terms and clinical doubt. While nomenclature is more settled with regards to ovarian mucinous neoplasms, the difficulty here lies with distinguishing primary from secondary mucinous tumours. This review highlights the terminology and nomenclature for appendiceal mucinous tumours, the relationship with ovarian mucinous neoplasms and pseudomyxoma peritonei, and the features that assist in separating primary from secondary ovarian mucinous tumours.
Subject(s)
Appendiceal Neoplasms/classification , Neoplasms, Cystic, Mucinous, and Serous/classification , Ovarian Neoplasms/classification , Terminology as Topic , Appendiceal Neoplasms/chemistry , Appendiceal Neoplasms/pathology , Biomarkers, Tumor/analysis , Diagnosis, Differential , Female , Humans , Immunohistochemistry , Male , Neoplasms, Cystic, Mucinous, and Serous/chemistry , Neoplasms, Cystic, Mucinous, and Serous/pathology , Ovarian Neoplasms/chemistry , Ovarian Neoplasms/pathology , Predictive Value of TestsABSTRACT
We report a case of appendicial paraganglioma in a 40 year old female who presented with acute appendicitis and underwent laparoscopic appendectomy. To the best of our knowledge this is the first reported case of appendicial gangliocytic paraganglioma with features suggestive of malignancy in the modern literature. Van Eeden S. et al. reported the first case of appendicial paraganglioma in a 47 year old man who also presented with acute appendicitis. The appendectomy specimen showed a distended appendix with thickened wall, and a 1.3 cm mucosal based yellow lesion. Microscopically this lesion was centered in the submucosa and consisted of three different cell types: (a) epithelioid cells with pale eosinophilic finely granular cytoplasm containing bland oval nucleus with stippled chromatin, that form solid nests lying in a trabecular pattern and in formations reminiscent of 'Zellballen' as seen in paragangliomas (b) second type cells have large vesicular nuclei with prominent nucleoli and abundant cytoplasm that are scattered singly, (c) third type cells with bland elongated nuclei form broad fascicle and envelop the epithelioid and ganglion cells. Immunohistochemical analysis showed the epithelioid cell nests immunoreactive for synaptophysin and the ganglion-like cells and spindle Schwann cells to be immunoreactive for S100 protein, whereas all three cells populations were negative for CAM5.2 and Pancytokeratin. We do believe that an accurate diagnosis of Gangliocytic paraganglioma (GP) of the appendix was rendered, detailed microscopic examination of doubled hematoxylin and eosinophil stained sections as well as the immunohistochemical phenotype of the three components have been undertaken to confirm the diagnosis of GP.